🇺🇸 FDA
Company

MADRIGAL

MADRIGAL PHARMACEUTICALS, INC.

MDGL pharma USA

Quick answer

MADRIGAL is a pharma company (MDGL) headquartered in WEST CONSHOHOCKEN, PA, USA with 14 tracked pipeline programs.

Pipeline (14)

project

MGL-3196

NASH - Nonalcoholic Steatohepatitis

Phase 3 · small_molecule · active

1 trials project

Placebo

Non-Alcoholic Fatty Liver Disease

Phase 3 · small_molecule · completed

1 trials project

Resmetirom

Non-Alcoholic Fatty Liver Disease

Phase 3 · small_molecule · active

1 trials project

Resmetirom

NASH

Phase 3 · small_molecule · active

1 trials project

MGL-3196

Non-alcoholic Steatohepatitis

Phase 2 · small_molecule · completed

1 trials project

MGL-3196 (resmetirom)

Heterozygous Familial Hypercholesterolemia

Phase 2 · small_molecule · completed

1 trials project

Resmetirom

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Phase 2 · small_molecule · active

1 trials project

100 mg Resmetirom Tablet

Renal Impairment

Phase 1 · small_molecule · completed

1 trials project

Atorvastatin

Healthy

Phase 1 · small_molecule · completed

1 trials project

MGL-3196

Hepatic Impairment

Phase 1 · small_molecule · completed

1 trials project

MGL-3196

Healthy

Phase 1 · small_molecule · completed

3 trials project

MGL-3196 Tablet

Healthy

Phase 1 · small_molecule · completed

1 trials project

Placebo

Drug Safety

Phase 1 · small_molecule · completed

2 trials project

Simvastatin

Healthy

Phase 1 · small_molecule · completed

1 trials

Drugs (1)

drug

resmetirom

REZDIFFRA

Patents (8)

patent

US 12377104

Methods for treating a fatty liver disease

Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11986481

Method of synthesizing thyroid hormone analogs and polymorphs thereof

Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11806353

Methods of treating liver disorders or lipid disorders with a THR-beta agonist

Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11564926

Methods of synthesizing thyroid hormone analogs and polymorphs thereof

Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11491145

Combination therapies comprising targeted therapeutics

Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11377447

Targeted therapeutics

Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11090308

Methods of treating liver disorders or lipid disorders with a THR-beta agonist

Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10894050

Methods of synthesizing thyroid hormone analogs and polymorphs thereof

Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)